This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

15 Aug 2021

Eliminating the Analytical Bottleneck in Production and Purification of mRNA

COVID-19 has focused a spotlight on the ability of mRNA technology to accelerate vaccine development and approval. That same technology can hasten the development and approval of other therapeutic classes, including cancer immunotherapy, protein replacement, and gene therapy. However, fulfilling those opportunities imposes significant challenges on process developers and manufacturers to improve existing processes.

Scale-up to produce millions of doses (tens of kilograms) compounds those challenges. Furthermore, every step of the journey requires high-performance analytical methods, to ensure patient safety and maximize productivity.

High-performance liquid chromatography (HPLC) has a long history of providing analytical data to support the development and manufacture of biologics, and it has unique capabilities for mRNA development. Benefits of HPLC include rapid results, high resolution, and quantitative monitoring, with minimal sample volume requirements.

Related News